CSB 2.008 Note
(or) 19-nor-4,9(10)-androstadienedione.
CSB 2.008 Note
(p) 19-nor-4-androstenedione (estr-4-en-3,17-dione).
CSB 2.008 Note
(pg) 19-nor-5-androstenedione (estr-5-en-3,17-dione).
CSB 2.008 Note
(pr) Norbolethone.
CSB 2.008 Note
(q) Norclostebol.
CSB 2.008 Note
(qg) Norethandrolone.
CSB 2.008 Note
(qr) Normethandrolone.
CSB 2.008 Note
(r) Oxandrolone.
CSB 2.008 Note
(rg) Oxymesterone.
CSB 2.008 Note
(rr) Oxymetholone.
CSB 2.008 Note
(s) Prostanozol.
CSB 2.008 Note
(sg) Stanozolol.
CSB 2.008 Note
(sr) Stenbolone.
CSB 2.008 Note
(t) Testolactone.
CSB 2.008 Note
(tg) Testosterone.
CSB 2.008 Note
(tr) Tetrahydrogestrinone.
CSB 2.008 Note
(u) Trenbolone.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2022 No. 800, eff. 7-25-22; correction made under s.
35.17, Stats.,
Register August 2022 No. 800;
CR 23-018: cr. Register April 2024 No. 820, eff. 5-1-24. CSB 2.008 Note
CSB 2.93 Addition of Daridorexant to schedule IV. Section
961.20 (2) (cpm), Stats., is created to read:
CSB 2.008 Note
961.20 (2) (cpm) Daridorexant;
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2022 No. 800, eff. 7-25-22; correction made under s.
35.17, Stats.,
Register August 2022 No. 800;
CR 23-019: cr. Register April 2024 No. 820, eff. 5-1-24; correction made under s. 35.17, Stats., Register April 2024 No. 820.
CSB 2.008 Note
CSB 2.94 Addition of seven (7) synthetic benzimidazole-opioid substances to schedule I. (1) Section 961.14 (2) (mm) and (pe), Stats., are renumbered to 961.14 (2) (xm) 3. and 5. and amended to read:
CSB 2.008 Note
961.14 (2) (xm) 3. Etonitazene (2-(2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1- amine).
CSB 2.008 Note
961.14 (2) (xm) 5. Isotonitazene (N,N -diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benizimidazol-1-yl)ethan-1-amine).
CSB 2.008 Note
961.14 (2) (xm) Synthetic Benzimidazole-opioid Substances, specifically including all of the following:
CSB 2.008 Note
1. Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1- amine).
CSB 2.008 Note
2. Etodesnitazene also known as Etazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1- amine).
CSB 2.008 Note
4. Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5- nitro-1H-benzimidazol-1-yl)ethan-1- amine).
CSB 2.008 Note
6. Metodesnitazene (N,N-diethyl-2-(2-(4- methoxybenzyl)-1H-benzimidazol-1- yl)ethan-1-amine).
CSB 2.008 Note
7. Metonitazene (N,N-diethyl-2-(2-(4- methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine).
CSB 2.008 Note
8. N-pyrrolidino etonitazene also known as etonitazepyne (2-(4-ethoxybenzyl)-5-nitro-1-(2- (pyrrolidin-1-yl)ethyl)-1H-benzimidazole).
CSB 2.008 Note
9. Protonitazene (N,N-diethyl-2-(5-nitro-2-(4- propoxybenzyl)-1H-benzimidazol-1- yl)ethan-1-amine).
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2022 No. 800, eff. 7-25-22; correction in numbering of (1), (2) made under s.
13.92 (4) (b) 1., Stats., and correction in (1) made under s.
35.17, Stats.,
Register August 2022 No. 800;
CR 23-020: cr. Register April 2024 No. 820, eff. 5-1-24; correction made under s. 35.17, Stats., Register April 2024 No. 820.
CSB 2.008 Note
CSB 2.95 Addition of Ganaxolone to schedule V. Section
961.22 (11), Stats., is created to read:
CSB 2.008 Note
961.22 (11) Ganaxolone. Ganaxolone.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2022 No. 800, eff. 7-25-22; (title) created under s.
13.92 (4) (b) 2., Stats,
Register August 2022 No. 800;
CR 23-021: cr. Register April 2024 No. 820, eff. 5-1-24; (title) created under s. 13.92 (4) (b) 2. Register April 2024 No. 820. CSB 2.008 Note
CSB 2.96 Addition of Amineptine to schedule I. Section
961.14 (7) (r), Stats., is created to read:
CSB 2.008 Note
961.14 (7) (r) 7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid, commonly known as Amineptine.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2023 No. 807, eff. 3-6-23; correction made under s.
35.17, Stats.,
Register March 2023 No. 807.
CSB 2.008 Note
CSB 2.97 Addition of Zipeprol to schedule I. Section
961.14 (2) (zm), Stats., is created to read:
CSB 2.008 Note
961.14 (2) (zm) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol).
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2023 No. 807, eff. 3-6-23.
CSB 2.008 Note
CSB 2.98 Excluding [18F]FP-CIT from schedule II. Section
961.16 (2) (b), Stats., is amended to read:
CSB 2.008 Note
961.16 (2) (b) Coca leaves and any salt, compound, derivative, or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [123I]Ioflupane is and [18 F]FP-CIT are excluded from this paragraph. The following substances and any of their salts, esters, isomers, and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2023 No. 807, eff. 3-6-23.
CSB 2.008 Note
CSB 2.99 Addition of Mesocarb to schedule I. Section
961.14 (7) (s), Stats., is created to read:
CSB 2.008 Note
961.14 (7) (s) N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate, commonly known as Mesocarb.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2023 No. 807, eff. 3-6-23.
